There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II …

Abstract “The Primate Malarias” book has been a uniquely important resource for multiple
generations of scientists, since its debut in 1971, and remains pertinent to the present day …

Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …

BACKGROUND The biology of Plasmodium vivax is markedly different from that of P.
falciparum; how this shapes the immune response to infection remains unclear. To address …

Plasmodium vivax is a malaria-causing pathogen that establishes a dormant form in the liver
(the hypnozoite), which can activate weeks, months, or years after the primary infection to …

The receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein
(PvDBPII) binds the Duffy antigen on the reticulocyte surface to mediate invasion. A …

We have previously reported primary endpoints of a clinical trial testing two vaccine
platforms for the delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA) …

Plasmodium vivax pre-erythrocytic (PE) vaccine research has lagged far behind efforts to
develop Plasmodium falciparum vaccines. There is a critical gap in our knowledge of PE …

The invasion of reticulocytes by Plasmodium vivax merozoites is dependent on the
interaction of the Plasmodium vivax Duffy Binding Protein (PvDBP) with the Duffy antigen …

The unique biology of Plasmodium vivax, with its ability to form latent hypnozoites in the liver
stage and the early appearance of gametocytes during blood stage infection, makes it …